Journal List > Kosin Med J > v.33(1) > 1122253

TOOLS
Park and Kwon: Are there differences in hepatitis-B immunization status between diabetes and non-diabetes subjects in Korea?
Original Article

Kosin Medical Journal 2018;33(1):41-50.

Published online: 21 January 2018

DOI: https://doi.org/10.7180/kmj.2018.33.1.41

Are there differences in hepatitis-B immunization status between diabetes and non-diabetes subjects in Korea?

Ji Young Park1, Su Kyoung Kwon2

1Department of Internal Medicine, Division of Infection, College of Medicine, Kosin University, Busan, Korea

2Department of Internal Medicine, Division of Endocrinology and Metabolism, College of Medicine, Kosin University, Busan, Korea

Corresponding Author: Su Kyoung Kwon, Department of Internal Medicine, College of Medicine, Kosin University, 262, Gamchen-ro, Seo-gu, Busan 49267, Korea Tel: +82-51-990-6712 Fax: +82-51-990-6712 E-mail: mir316@naver.com

Received 21 October 201614 November 2016       Accepted 26 December 2016

Copyright © 2018 Kosin University School of Medicine Proceedings

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objectives

The American Diabetes Association (ADA) recommends hepatitis-B virusVIruS vaccination for unvaccinated adults with diabetes. However, the Korean Diabetes Association (KDA) did not recommend hepatitis-B vaccination for unvaccinated adults with diabetes. This study was performed to assess the differences in hepatitis-B virus antigen and antibody status between Korean patients with diabetes and those without by using national survey data.

Methods

We analyzed hepatitis-B virus antigen and antibody status in 9,771 South Korean people from the general population based on the Korean National Health and Nutrition Examination Survey. Diabetes patients were defined as those with a measured fasting plasma glucose over 126 mg/dL or those who had been previously diagnosed with diabetes by other health care centers.

Results

Subjects with diabetes accounted for 812 (8.3%) among the 9771 study subjects. The prevalence ofhepatitis-B (HBsAg) seropositive subjects was not significantly different (3.9% vs. 4.6%, P = 0.09) between subjects with diabetes and those without. The prevalence of hepatitis-B antibody (HBsAb) positive subjects and unimmunized subjects was not significantly different (55.2% vs. 58.2%, P = 0.09, 40.9% vs. 37.2%, P = 0.09) between the two groups. The prevalence of unimmunized subjects decreased by age (< 20 years 33.3 % vs. 33.0%, 20~29 years 49.1% vs. 41.2%, 30~39 years 41.9% vs. 37.7%, 40~49 years 35.1% vs. 33.5%, 50~59 years 39.0% vs. 38.0%, 60~69 years 41.2% vs. 39.8%, > 70 years 48.5% vs. 42.8%) but was not significantly different between the 2 groups.

Conclusions

From this study, we conclude that there are not sufficient grounds to recommend routine hepatitis-B virus vaccination for unvaccinated Korean subjects with diabetes at this point in time in Korea. Further prospective studies will be needed.

Keywords: Diabetes, Hepatitis B, Immunization, Korean National Health and Nutrition

REFERENCES

1.Emerging Risk Factors Collaboration. Seshasai SR., Kaptoge S., Thompson A., Di Angelantonio E., Gao P, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011. 364:829–41.
crossref
2.American Diabetes Association. 3. Foundations of Care and Comprehensive Medical Evaluation. Diabetes Care. 2016. 39:S23–35.
3.Treatment Guidelines for Diabetes (5th edition) [Internet]. Korean Diabetes Association. Available from:. http://www.diabetes.or.kr/pro/pub-lishlguide.php?mode=list.
4.Bender TJ., Wise ME., Utah O., Moorman AC., Sharapov U., Drobeniuc J, et al. Outbreak of hepatitis B virus infections associated with assisted monitoring of blood glucose in an assisted living facility-Virginia, 2010. PLoS One. 2012. 7:e50012.
crossref
5.Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011. 60:1709–11.
6.Jeong S., Yim HW., Bae SH., Lee WC. Changes of Hepatitis B Surface Antigen Seroprevalence in Korea, 1998-2005. Korean J Epidemiol. 2008. 30:119–27. Korean.
crossref
7.Thompson ND., Perz JF. Eliminating the blood: ongoing outbreaks of hepatitis B virus infection and the need for innovative glucose monitoring technologies. J Diabetes Sci TechnoI. 2009. 3:283–8.
crossref
8.Centers for Disease Control and Prevention(CDC). Transmission of hepatitis B VIruS among persons undergoing blood glucose monitoring in long-term--care facilities- Mississippi, North Carolina, and Los Angeles County, California, 2003-2004. MMWR Morb Mortal Wkly Rep. 2005. 54:220–3.
9.Reilly ML., Poissant T., Vonderwahl CW., Gerard K., Murphy TV. Incidence of acute hepatitis B among adults with and without diabetes, 2009-2010. 49th Annual Meeting of the Infectious Disease Society of America and the HIV Medicine Association; Boston, MA, October. 2011.
10.Younossi ZM., Gramlich T., Matteoni CA., Boparai N., McCullough AI. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004. 2:262–5.
crossref
11.Mehta SH., Brancati FL., Sulkowski MS., Strathdee SA., Szklo M., Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med. 2000. 133:592–9.
crossref
12.Antonelli A., Ferri C., Fallahi P., Pampana A., Ferrari SM., Goglia F, et al. Hepatitis C virus infection: evidence for an association with type 2 diabetes. Diabetes Care. 2005. 28:2548–50.
crossref
13.Hyams KC. Risks of chronicity following acute hepatitis B virus infection: a review. Clin Infect Dis. 1995. 20:992–1000.
crossref
14.El-Serag HB., Tran T., Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004. 126:460–8.
crossref
15.Klonoff DC., Perz JF. Assisted monitoring of blood glucose: special safety needs for a new paradigm in testing glucose. J Diabetes Sci TechnoI. 2010. 4:1027–31.
crossref
16.Samandari T., Malakmadze N., Balter S., Perz IF., Khristova M., Swetnam L, et al. A large outbreak of hepatitis B virus infections associated with frequent injections at a physician's office. Infect Control Hosp Epidemiol. 2005. 26:745–50.
crossref
17.Mast EE., Weinbaum CM., Fiore AE., Alter MJ., Bell BP., Finelli L, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) partII: immunization of adults. MMWR Recomm Rep. 2006. 55(No.RR-16):1–13.

Fig. 1.
Distribution of hepatitis-B immunization status among diabetes and non-diabetes subjects.
kmj-33-41f1.tif
Table 1.
Baseline characteristics of study subjects
Variables Diabetes (n = 812) Non diabetes (n = 8959) P-value
Male : Female 415:397 4095:4864 0.021
Age, years 51.66 ± 15.67 37.91 ± 18.07 < 0.001
Weight, Kg 62.07 ± 10.81 58.8 ± 11.34 < 0.001
BMI, kg/m2 24.02 ± 3.41 22.47 ± 3.38 < 0.001
Waistcircumference(WC) 84.87 ± 9.34 77.75 ± 10.14 < 0.001
SBP, mmHg 134 ± 20.76 122.74 ± 18.75 < 0.001
DBP, mmHg 80.75 ± 12.44 75.99 ± 12.53 < 0.001
Pulserate, bpm 76.13 ± 10.88 74.02 ± 10.40 < 0.001
AST, U/L 51.66 ± 15.67 26.91 ± 18.52 < 0.001
ALT, U/L 33.84 ± 29.725 25.59 ± 21.30 < 0.001
Fastingbloodglucose, mg/dL 163.25 ± 62.04 93.65 ± 12.82 < 0.001
WBC, × 103/μL 6.15 ± 1.83 6.20 ± 18.28 0.947

Data are presented by mean ± standard deviation.

N, number; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; bpm, beats per minuite; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cell.

Table 2.
Age and Obesity adjusted means of liver function
Variables Diabetes (n = 812) Non diabetes (n = 8959) P-value
Aspartate aminotransferase, AST, SGOT* 30.71 ± 0.69 27.07 ± 0.21 < 0.001
Alanine aminotransferase, ALT, SGPT* 31.35 ± 0.75 25.83 ± 0.23 < 0.001
AST** 30.12 ± 0.69 27.13 ± 0.21 < 0.001
ALT** 30.17 ± 0.75 25.95 ± 0.23 < 0.001

Data are presented by mean ± standard error

* Adujusted by age and body mass index.

** Adjusted by age, body mass index and waist circumference.

Table 3.
Distribution of hepatitis-B immunization status according to different age groups by diabetes status
Age Groups Non-diabetes Diabetes P-value
HBV carrier Immunized Non-immunized HBV carrier Immunized Non-immunized
Total(%) 408 (4.6%) 5189(58.2%) 3313 (37.2%) 36 (3.9%) 477 (55.2%) 348 (40.9%) 0.169
<20 42 (2.4%) 1152 (64.6%) 588 (33.0%) 1 (3.7%) 17 (63%) 9 (33.3%) 0.898
20-30 81 (5.6%) 764 (53.1%) 593 (41.2%) 0 (0.0%) 28 (50.9%) 27 (49.1%) 0.140
30-40 115 (6.2%) 1033 (56.0%) 696 (37.7%) 8 (6.5%) 64 (51.6%) 52 (41.9%) 0.622
40-50 77 (5.1%) 918 (61.4%) 501 (33.5%) 5 (3.7%) 82 (61.2%) 47 (35.1%) 0.747
50-60 63 (6.0%) 588 (56.0%) 396 (38.0%) 6 (2.9%) 122 (58.1%) 82 (39.0%) 0.188
60-70 21 (2.5%) 486 (57.7%) 335 (39.8%) 10 (6.1%) 87 (52.7%) 68 (41.2%) 0.078
70-80 10 (2.5%) 218 (54.1%) 175 (43.4%) 1 (1.1%) 45 (51.1%) 42 (47.7%) 0.605
≥ 80 3 (3.2%) 54 (57.4%) 37 (39.4%) 1 (5.3%) 8 (42.1%) 10 (52.6%) 0.463

HBV, hepatitis B virus; Immunozed, HBsAg (-) and HBsAb (+); Non-immunized, HBsAg (-) and HBsAb (-)

TOOLS
Similar articles